Top Neurology Research Papers

Overall: A strong meta-analysis of randomized trials demonstrates meaningful functional improvement from imaging-selected extended-window thrombolysis, although increased symptomatic hemorrhage and the need for advanced stroke workflows temper the net benefit.

Overall: A well-conducted randomized trial found a large improvement in 90-day functional independence using a feasible, reperfusion-guided blood pressure strategy, with no evident increase in major safety outcomes.

Overall: This large, rigorous trial found a modest but clinically meaningful reduction in recurrent ischemic stroke without a demonstrated increase in major bleeding, making the findings likely to influence secondary prevention practice.

Overall: A well-designed phase 3 trial found a very large, clinically important reduction in NMOSD relapse without an observed increase in severe treatment-related adverse events, though the small cohort, limited follow-up, and infusion burden reduce certainty and practicality.

Overall: A strong randomized trial found a clinically meaningful reduction in recurrent stroke with a practical single-pill regimen, offset by substantially more treatment discontinuation and limited applicability beyond intracerebral-hemorrhage survivors.

Overall: This uncontrolled but informative five-year extension reports substantial survival, respiratory, feeding, and motor benefits with no new safety signal, while its small selected cohort and lack of a comparator limit causal certainty and independent practice-changing impact.

Overall: Fixed-Dose Tavapadon for Early Parkinson Disease: A Randomized Clinical Trial — A strong phase 3 trial found substantial short-term motor and functional improvement with convenient dosing, but specialty involvement, common adverse effects, limited patient-reported results, and the absence of an active comparator constrain immediate primary-care impact.

Overall: A large, clinically relevant observational analysis identifies potentially important differences in thrombosis, bleeding, and mortality across antiseizure medications, but residual confounding and missing absolute risks limit definitive treatment recommendations.

Overall: This large, long-running US cohort study provides precise and clinically relevant associations between greater physical activity and better cognitive outcomes, but its observational design, absent absolute effects, and confirmation of existing advice limit causal and practice-changing impact.

Overall: Management of Exacerbations and Rescue Therapy: A Prespecified Analysis of the Phase 3 Myasthenia Gravis Inebilizumab Randomized Clinical Trial showed a credible and clinically important reduction in exacerbations, but missing absolute effects, safety findings, and implementation details temper its immediate impact.